This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Strong Sell Stocks for April 11th
by Zacks Equity Research
DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on April 11, 2022.
New Strong Sell Stocks for March 25th
by Zacks Equity Research
DDD, ADAP, and ADV have been added to the Zacks Rank #5 (Strong Sell) List on March 25, 2022.
New Strong Sell Stocks for March 17th
by Zacks Equity Research
DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on March 17, 2022.
Tenet Healthcare (THC) Up 55% in a Year: Is More Upside Left?
by Zacks Equity Research
Growing revenues, strong performances exhibited by segments, numerous acquisitions and sturdy financial standing continue to drive Tenet Healthcare (THC).
Gilead's (GILD) Trodelvy Late-Line Breast Cancer Study Meets Goal
by Zacks Equity Research
While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results.
Puma Biotech (PBYI) Q4 Earnings Beat Mark, Revenues Rise Y/Y
by Zacks Equity Research
Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.
Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.
Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
After Plunging 19.1% in 4 Weeks, Here's Why the Trend Might Reverse for Adaptimmune Therapeutics PLC (ADAP)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Adaptimmune Therapeutics PLC (ADAP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.
Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag
by Zacks Equity Research
Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat
by Zacks Equity Research
Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.
Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.
CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.
Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.
4 Biotechs That Could Be Potential Takeover Targets in 2022
by Ekta Bagri
We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.
Vertex's (VRTX) Early Type I Diabetes Study Data Promising
by Zacks Equity Research
Vertex's (VRTX) single infusion drug candidate, VX-880, for type I diabetes shows restoration of insulin production and robust improvements in multiple measures in a phase I/II study
Can Adaptimmune (ADAP) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Adaptimmune (ADAP) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and BioMarin (BMRN), among others, have been in focus in the biotech industry over the past week.
Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies
by Zacks Equity Research
Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.
Adaptimmune (ADAP) Presents Data on Liver Cancer Candidate
by Zacks Equity Research
Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.
Implied Volatility Surging for Adaptimmune Therapeutics (ADAP) Stock Options
by Aditi Saraogi
Investors need to pay close attention to for Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.
All You Need to Know About Adaptimmune Therapeutics PLC (ADAP) Rating Upgrade to Buy
by Zacks Equity Research
Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Growth Investing Leads in 1H: 5 Top ETFs & Stocks
by Sweta Killa
Growth investing took a lead so far this year courtesy of massive money flowing into the economy.